Washed Microbiota Transplantation for Allergic Rhinitis

Status Not yet recruiting

Clinical Trial Summary

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

Clinical Trial Description

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. The prevalence of AR has been reported from 5% to 50% worldwide which is dependent on the method of diagnosis and age of participants studied. AR is often co-morbid with asthma and/or conjunctivitis, which affects patients' daily life and carries a huge economic burden. Increasing evidence showed that gut microbiota can influence the development of AR. Fecal Microbiota transplantation (FMT), the most classic way to treat diseases using gut microbiota, refers to the transplantation of functional microbiota in the feces of healthy people into the intestines of patients. It can reconstruct the overall gut microbiota of patients, thus treating gastrointestinal disease and external gastrointestinal diseases of patients. Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. Compared with manual FMT, WMT can reduce the rate of adverseevents (such as fever, diarrhea, abdominal pain, abdominal distension, nausea and vomiting, etc.) without affecting the efficacy. In clinical practice, we found that WMT could significantly improve the nasal symptoms of AR. This clinical trial aims to evaluate the efficacy and safety of WMT for AR. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06372184
Study type	Interventional
Source	The Second Hospital of Nanjing Medical University
Contact	Faming Zhang, MD,PhD
Phone	086-25-58509883
Email	fzhang@njmu.edu.cn
Status	Not yet recruiting
Phase	N/A
Start date	June 1, 2024
Completion date	October 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02424539` - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)	Phase 4
Completed	`NCT02486159` - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture	N/A
Completed	`NCT00770315` - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)	Phase 3
Completed	`NCT00771160` - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)	Phase 3
Completed	`NCT00834119` - Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)	Phase 4
Recruiting	`NCT04435990` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites	Phase 3
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting	`NCT05621356` - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting	`NCT06330974` - Allergy, Asthma, and Atopic Eczema in Finland
Completed	`NCT03758456` - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human	Phase 1
Completed	`NCT04645979` - A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed	`NCT05122143` - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers	N/A
Completed	`NCT05901532` - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis	Phase 2
Terminated	`NCT02722083` - Exploratory Study for Allergy Relief Onset	Phase 2
Recruiting	`NCT05656482` - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting	`NCT04898283` - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.	Phase 3
Recruiting	`NCT05922176` - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed	`NCT02679105` - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy	Phase 2/Phase 3
Completed	`NCT01104012` - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis	N/A
Completed	`NCT03375775` - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children	N/A